Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
- Next story Using light to monitor cancer
- Previous story New heart metric may improve survival for heart-failure patients, study finds
Explore more
- These locally elected officials posted or openly supported QAnon conspiracy theories. Here’s what happened after they took office
A normally orderly school board meeting in this small city began with... - Takeaways From Day 10 of the Derek Chauvin Trial
The medical examiner who performed the initial autopsy of George Floyd said... - European Space Agency wants to build a GPS network for the moon
ESA wants to creating a network of satellites in orbit around the... - U.S. Put Gag Order on Times Executives Amid Fight Over Email Logs
A push by prosecutors to secretly seize data about four Times reporters’... - Perseverance rover’s first-ever selfie also shows Mars helicopter
NASA’s Perseverance rover has snapped its first-ever Mars selfie, with the about-to-fly... - Heart health of shift workers linked to body clock
Working hours that deviate from an individual’s natural body clock are associated... - Best Memorial Day phone deals and sales for 2021
If you’re in the market for a new mobile, then Memorial Day... - This 65-inch 4K TV is so cheap at Best Buy it might be a mistake
Best Buy is offering the Insignia 65-inch Class F30 LED 4K UHD... - 50% of US adults expected to have at least one jab by end of this week
- Small uveal melanomas ‘not always harmless’, study finds
A new article from Liverpool ocular researchers demonstrates that small uveal (intraocular)...